Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant

Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant

Abstract Background p53, the most frequently mutated gene in cancer, lacks effective targeted drugs. Methods We developed monoclonal antibodies (mAbs) that target a p53 hotspot mutation E285K without cross-reactivity with wild-type p53. They were delivered using lipid nanoparticles (LNPs) that encap...

Full description

Bibliographic Details
Main Authors: Dafei Chai, Junhao Wang, Chunmei Fan, Jing-Ming Lim, Xu Wang, Praveen Neeli, Xinfang Yu, Ken H. Young, Yong Li
Format: Article
Language:English
Published: BMC 2024-06-01
Series:Journal of Hematology & Oncology
Subjects:
Mutant p53
E285K
Monoclonal antibody
IgG1
dIgA
Online Access:https://doi.org/10.1186/s13045-024-01566-1

Internet

https://doi.org/10.1186/s13045-024-01566-1

Similar Items